Search by Drug Name or NDC
NDC 62856-0704-30 Lenvima 4 mg/1 Details
Lenvima 4 mg/1
Lenvima is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eisai Inc.. The primary component is LENVATINIB.
MedlinePlus Drug Summary
Lenvatinib is used to treat a certain type of thyroid cancer that has returned or that has spread to other parts of the body and cannot be treated with radioactive iodine. Lenvatinib is also used along with everolimus (Afinitor, Zortress) to treat renal cell carcinoma (RCC, a type of cancer that begins in the kidney) in people who have previously received treatment with another chemotherapy medication. Lenvatinib is also used along with pembrolizumab (Keytruda) as an initial treatment for advanced renal cell carcinoma. Lenvatinib is also used to treat hepatocellular carcinoma (HCC; a type of liver cancer) that cannot be treated with surgery. Lenvatinib is also used along with pembrolizumab (Keytruda) to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other parts of the body or worsened during or after treatment with chemotherapy medications or that cannot be treated with surgery or radiation therapy. Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Related Packages: 62856-0704-30Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Lenvatinib
Product Information
| NDC | 62856-0704 |
|---|---|
| Product ID | 62856-704_81790f87-5788-495a-b299-68e56840a700 |
| Associated GPIs | 2133505420B210 |
| GCN Sequence Number | 074284 |
| GCN Sequence Number Description | lenvatinib mesylate CAPSULE 4 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 38885 |
| HICL Sequence Number | 041756 |
| HICL Sequence Number Description | LENVATINIB MESYLATE |
| Brand/Generic | Brand |
| Proprietary Name | Lenvima |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Lenvatinib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 4 |
| Active Ingredient Units | mg/1 |
| Substance Name | LENVATINIB |
| Labeler Name | Eisai Inc. |
| Pharmaceutical Class | Kinase Inhibitor [EPC], Receptor Tyrosine Kinase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA206947 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 62856-0704-30 (62856070430)
| NDC Package Code | 62856-704-30 |
|---|---|
| Billing NDC | 62856070430 |
| Package | 6 BLISTER PACK in 1 BOX, UNIT-DOSE (62856-704-30) / 5 CAPSULE in 1 BLISTER PACK (62856-704-05) |
| Marketing Start Date | 2018-08-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |